Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of PTEN (green) showing staining in the cytoplasm of NIH-3T3 cells (right) compared to a negative control without primary antibody (left). Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a PTEN monoclonal antibody (Product # MA5-12278) in 3% BSA-PBS at a dilution of 1:10 and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-conjugated secondary antibody in PBS at room temperature in the dark. F-actin (red) was stained with a flourescent red phalloidin and nuclei (blue) were stained with Hoechst or DAPI. Images were taken at a magnification of 60x.
|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgM, kappa|
|Immunogen||Recombinant human PTEN protein|
|Storage buffer||tissue culture supernatant|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:200|
|Western Blot (WB)||1:10-1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12278 targets PTEN in WB, IHC and ICC/IF applications and shows reactivity with Human and Mouse samples.
The MA5-12278 immunogen is recombinant human PTEN protein.
This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy.
MA5-12278 was used in immunohistochemistry to study EGFR signaling pathway components in primary colorectal cancer and paired metastases
|Cejas P,López-Gómez M,Aguayo C,Madero R,Moreno-Rubio J,de Castro Carpeño J,Belda-Iniesta C,Barriuso J,Moreno García V,Díaz E,Burgos E,Gonzalez-Barón M,Feliu J||Current cancer drug targets (12:124)||2012|
Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
MA5-12278 was used in immunohistochemistry to investigate the effectiveness of PTEN and p53 for the prognosis of ovarian carcinomas
|Skírnisdóttir I,Seidal T||International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (21:1024)||2011|
Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma.
MA5-12278 was used in immunohistochemistry to study the potential prognostic value of EGFR pathway markers in synovial sarcoma
|Teng HW,Wang HW,Chen WM,Chao TC,Hsieh YY,Hsih CH,Tzeng CH,Chen PC,Yen CC||Journal of surgical oncology (103:773)||2011|
Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer.
MA5-12278 was used in immunohistochemistry to investigate the efficacy of docetaxel and trastuzumab against locally advanced HER-2-overexpressing breast cancer
|Sawaki M,Iwata H,Sato Y,Wada M,Toyama T,Sasaki E,Yatabe Y,Imai T,Ohashi Y||Breast (Edinburgh, Scotland) (19:370)||2010|
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
MA5-12278 was used in immunohistochemistry to study PIK3CA mutations in ductal carcinoma of the breast
|Li H,Zhu R,Wang L,Zhu T,Li Q,Chen Q,Wang H,Zhu H||Experimental and molecular pathology (88:150)||2010|
Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified.
MA5-12278 was used in immunohistochemistry to study the level of PTEN in peripheral T-cell lymphoma
|Gazzola A,Bertuzzi C,Agostinelli C,Righi S,Pileri SA,Piccaluga PP||Haematologica (94:1036)||2009|
Comparison of placental PTEN and beta1 integrin expression in early spontaneous abortion, early and late normal pregnancy.
MA5-12278 was used in immunohistochemistry to investigate the changes of PTEN and beta1 integrin in different stages of pregnancy and pregnancy termination
|Tokyol C,Aktepe F,Hüsniye Dilek F,Yilmazer M||Upsala journal of medical sciences (113:235)||2008|
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
MA5-12278 was used in immunohistochemistry to study EGF receptor pathway activation in completely resected non-small cell lung cancer
|Volante M,Saviozzi S,Rapa I,Ceppi P,Cappia S,Calogero R,Novello S,Borasio P,Papotti M,Scagliotti GV||Cancer (110:1321)||2007|
PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
MA5-12278 was used in immunohistochemistry to examine the role of PIK3CA mutations and PTEN loss in the carcinogenesis of breast cells
|Pérez-Tenorio G,Alkhori L,Olsson B,Waltersson MA,Nordenskjöld B,Rutqvist LE,Skoog L,Stål O||Clinical cancer research : an official journal of the American Association for Cancer Research (13:3577)||2007|
Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index.
MA5-12278 was used in immunohistochemistry to investigate the expression of PTEN in normal, hyperplastic and malignant endometrium
|Kapucuoglu N,Aktepe F,Kaya H,Bircan S,Karahan N,Ciriş M||Pathology, research and practice (203:153)||2007|
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
MA5-12278 was used in immunohistochemistry to examine the involvement of neutral endopeptidase in prostate cancer progression
|Osman I,Dai J,Mikhail M,Navarro D,Taneja SS,Lee P,Christos P,Shen R,Nanus DM||Cancer (107:2628)||2006|
PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations.
MA5-12278 was used in immunohistochemistry to study the role of PTEN mutations in low-grade endometrioid tumors
|Kolasa IK,Rembiszewska A,Janiec-Jankowska A,Dansonka-Mieszkowska A,Lewandowska AM,Konopka B,Kupryjańczyk J||Gynecologic oncology (103:692)||2006|
Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer.
MA5-12278 was used in immunohistochemistry to study the relationship between survivin and PTEN expression and prognosis in gastric cancer
|Deng H,Wu RL,Zhou HY,Huang X,Chen Y,Liu LJ||World journal of gastroenterology (12:1013)||2006|
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.
MA5-12278 was used in immunohistochemistry to study the prognostic value of the erb-b signaling pathway in advanced ovarian carcinomas
|Wang Y,Kristensen GB,Helland A,Nesland JM,Børresen-Dale AL,Holm R||American journal of clinical pathology (124:392)||2005|
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.
MA5-12278 was used in immunohistochemistry to study the role of PTEN signaling pathways in breast cancer
|Panigrahi AR,Pinder SE,Chan SY,Paish EC,Robertson JF,Ellis IO||The Journal of pathology (204:93)||2004|
Proliferation kinetics in adenomyosis during the menstrual cycle and during oral contraceptive use.
MA5-12278 was used in immunohistochemistry to study the expression of p53 in adenomyosis during the menstrual cycle and during oral contraceptive use
|Maia H,Maltez A,Studart E,Athayde C,Coutinho EM||Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (18:101)||2004|
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
MA5-12278 was used in western blot to study the role of miR-29 in B-cell chronic lymphocytic leukemia
|Santanam U,Zanesi N,Efanov A,Costinean S,Palamarchuk A,Hagan JP,Volinia S,Alder H,Rassenti L,Kipps T,Croce CM,Pekarsky Y||Proceedings of the National Academy of Sciences of the United States of America (107:12210)||2010|
4; 5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; mitochondrial phosphatase and tensin protein alpha; mitochondrial PTENalpha; MMAC1; MMAC1 phosphatase and tensin homolog deleted on chromosome 10; mutated in multiple advanced cancers 1; phosphatase and tensin-like protein; Phosphatidylinositol 3; phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; TEP1
10q23del; BZS; CWS1; DEC; GLM2; MHAM; MMAC1; PTEN; PTEN1; TEP1